HindustanTimes Sat,19 Apr 2014

Novartis India says will continue to file for patents

Reuters  Mumbai, April 01, 2013
First Published: 15:22 IST(1/4/2013) | Last Updated: 15:23 IST(1/4/2013)

Novartis India Ltd, a unit of Swiss drugmaker Novartis AG, will continue to file for patents in India, its vice chairman said on Monday, after the the Supreme Court rejected its plea for patent protection of its drug Glivec.


Novartis India will also continue to invest there, but with caution, Ranjit Shahani, who is also the managing director of the company, told reporters after the Supreme Court judgment.

Earlier on Monday, the court dismissed Novartis' petition seeking patent protection for cancer drug Glivec, a serious blow to Western pharmaceutical firms who are increasingly focusing on India to drive sales.

more from Business

700 trainees opt for exit plan at Nokia’s Chennai plant

Finnish handset maker Nokia, struggling to shepherd its Chennai plant into its agreement to be bought by US software giant Microsoft amid tax disputes in India, has got some success with 736 of its trainees accepting the voluntary separation scheme.
Most Popular
Copyright © 2014 HT Media Limited. All Rights Reserved